Harmony Biosciences Holdings, Inc. reports preliminary Q2 results (HRMY:NASDAQ)

Harmony Biosciences (HRMY) Q2 revenue hits $261M; 2026 guidance reaffirmed at $1.0B–$1.04B. Get key insights before Aug.

Harmony Biosciences Holdings, Inc. reports preliminary Q2 results (HRMY:NASDAQ) | Seeking Alpha

Save

Play

(

<1min

)

Comments

Harmony Biosciences Holdings, Inc.

press release

(

HRMY

): Q2 Revenue of $261M.

Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion

Â

Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026

More on Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. (HRMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Harmony Biosciences Holdings, Inc. 2026 Q1 - Results - Earnings Call Presentation

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript

Harmony Bio drops after CFO exit

Harmony outlines $1B-$1.04B 2026 net revenue plan while targeting pitolisant GR PDUFA in Q1 2027

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please

report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search field

Entering text into the input field will update the search result below

Entering text into the input field will update the search result below

Recommended For You

More

Trending News

See More

»